According to MarketBeat.com, the six research companies that cover Elanco Animal Health Incorporated (NYSE: ELAN-Get Rating) gave the company an average rating of “Hold,” indicating investors should maintain their current position in the title. Six equity research analysts suggest keeping the stock in your portfolio, while the other five suggest selling it. Analysts who have reviewed the company have decided that the price target for next year should be $23.33, which is roughly what is expected. The most recent research that analysts have conducted has primarily focused on ELAN. Elanco Animal Health was downgraded by Goldman Sachs Group from a “buy” rating to a “sell” rating in a report released Thursday, July 21. Additionally, Goldman Sachs Group has reduced its price target for the company from $32 to $19.00. These two actions were included in the report. The report contains this material in its entirety. In a research report released Tuesday, August 16, Piper Sandler lowered her price target on Elanco Animal Health from $22.00 to $21.00.
She gave the company a “neutral” rating in a research report. Again, it was Elanco Animal Health that the report was about. In a research note published Thursday, August 18, Morgan Stanley lowered its price target for Elanco Animal Health from $37.00 to $22.00, downgrading the company from “overweight” to “equal weight.” Elanco Animal Health’s rating, which was previously rated as “overweight”, has been adjusted due to this decision. In a research report published on Friday, June 24, Stifel Nicolaus gave the company a “holding” rating in a research report and lowered its price target on Elanco Animal Health from $30.00 to $22.00. $ due to business performance. Again, it was Elanco Animal Health that the report was about. In a research note published Tuesday, August 16, JPMorgan Chase & Co. lowered its price target for Elanco Animal Health from $28.00 to $24.00 and changed its rating for the company from “overweight” to “neutral” in a research note that was published on Tuesday, August 16.
NYSE: ELAN had its first day of trading on Friday, and the opening price was $15. The company is currently trading at a price/earnings ratio of -42.86, a price/earnings/growth ratio of 1.49 and a beta value of 0.87. His current market value is $7.11 billion. According to the price/earnings/growth ratio, the company is expected to grow at a rate of 1.49 over the next few years. The current gear is 2.47, the quick gear is 1.47, and the current gear is 1.47. The debt ratio is 0.84, the current ratio is 2.47, the quick ratio is 1.47 and the current ratio is 1.47. The company’s stock price moving average over the past 200 days is $22.51, while its stock price moving average over the past 50 days is $18.51. Over the past year, the price of Elanco Animal Health has fluctuated between $13.94 and $35.00. The current price is $13.94. The company disclosed that its quarterly earnings per share were $0.36, $0.10 higher than analysts’ average projection of $0.26. The company’s actual sales for the quarter were $1.18 billion, significantly lower than the company’s typical sales forecast of $1.18 billion. In addition, 3.77% was the net margin earned by Elanco Animal Health and 7.40% was the return on equity generated by the company. The company recorded a lower revenue decline of 8.0% compared to the total for the same quarter of the previous year. The company earned $0.28 per share, compared to its results in the same period a year earlier. According to stock analysts’ projections, Elanco Animal Health will generate earnings per share of $1.09 in 2018.
On September 9, insider Rajeev A. Modi bought 6,700 shares of the company. The transaction took place on Friday. Another news item from Elanco Animal Health revealed this information. It was acquired through the acquisition of shares with a total value of $99,830.00, which corresponds to an average price of $14.90 per share. The insider now directly owns 41,157 shares of the company, which have a combined value of $613,239.30 as a direct result of the transaction. If you follow this link, you will be redirected to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed. You can just ignore this link if you don’t want to follow it. On September 9, insider Rajeev A. Modi bought 6,700 shares of the company. The transaction took place on Friday. Another news item from Elanco Animal Health revealed this information. It was acquired through the acquisition of shares valued at $99,830.00, which corresponds to an average price of $14.90 per share. The insider now directly owns 41,157 shares, which have a combined value of $613,239.30 as a direct result of the transaction. If you follow this link, you will be redirected to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed.
You can just ignore this link if you don’t want to follow it. On Friday, September 9, Elanco Animal Health Manager R. David Hoover purchased 20,000 shares of the company. The number of shares was acquired for a total price of $303,600.00, which corresponds to an average price of $15.18 per share. As a direct result of the operation, the manager now owns 145,000 shares in the company. The total value of these shares is $2,201,100. You should look here if you are looking for disclosure related to this transaction. Business insiders have spent a combined $839,630 over the past three months and ninety days to buy 56,700 shares of the company. Insiders hold 6.40% of the total number of shares currently issued in the company. A range of hedge funds and institutional investors have been seen engaging in recent activity buying and selling ELAN shares. During the last three months of 2018, Qube Research & Technologies Ltd. made a purchase that resulted in the acquisition of a new stake in Elanco Animal Health for a total payment of $18,310,000. ProShare Advisors LLC’s Elanco Animal Health stock portfolio rose 5.9% in the last three months of 2018.
As a result, ProShare Advisors LLC now owns a total of 11,910 shares of the company, which are worth a combined total of $338,000 following the purchase of 667 additional shares during the last fiscal quarter. During the fourth quarter reporting period, Dimensional Fund Advisors LP increased the total number of Elanco Animal Health shares held by 7.3%. Following the acquisition of an additional 180,282 shares during the last quarter, Dimensional Fund Advisors LP now holds 2,645,122 shares of the company in its portfolio. The total value of the company’s interests is estimated to be nearly $75,075,000. Additionally, UMB Bank, National Association of Missouri, purchased $111,000 worth of Elanco Animal Health stock during the last fiscal quarter. And finally, in the last three months of 2018, HighTower Advisors LLC increased the shares of Elanco Animal Health it held by 22.2%, bringing its total percentage to 100%. HighTower Advisors LLC now owns a total of 135,747 shares of the company after purchasing an additional 24,698 shares in the last quarter. The value of HighTower Advisors LLC’s holdings in the company is $3,842,000. Financial institutions hold most of the shares, accounting for 98.15% of the total.
Elanco Animal Health Incorporated is dedicated to creating new products, developing new products, manufacturing new products and selling products relevant to the health of pets and agricultural animals. Its business is to sell vaccines, antibiotics, parasiticides and other items that can be used in poultry and aquaculture production. It also sells products that protect pets against worms, fleas and ticks under Seresto, Advantage, Advantix and Advocate. She also sells medications for dogs and cats that treat pain, osteoarthritis, ear infections, heart disease and skin conditions. These drugs are sold under the brand names Galliprant and Claro. MarketBeat tracks the most reputable and successful research analysts working on Wall Street and the companies these analysts recommend to their clients daily. MarketBeat also tracks the companies that these analysts study closely. MarketBeat found five companies whose top analysts are wrongly encouraging their consumers to buy now before the rest of the market realizes the trend. Unfortunately, Elanco Animal Health was not one of those five companies.